XÜLASƏ
Bu məqalədə iltihabi bağırsaq xəstəlikləri (İBX) zamanı oynaq sindromunun klinik xüsusiyyətləri, diaqnostikası və differensial diaqnostikası ilə bağlı müasir məlumatlar təqdim edilmişdir. Oynaqların zədələnməsinin əsas formaları, o cümlədən I və II tip periferik artropatiyalar, aksial və periferik spondiloartrit, entezit və daktilit nəzərdən keçirilmişdir. Oynaq sindromunun klinik təzahürlərinə, onun bağırsaq iltihabının aktivliyi ilə əlaqəsinə, həmçinin vaxtında diaqnostikanı çətinləşdirən amillərə xüsusi diqqət yetirilmişdir. İBX-nin oynaq təzahürlərinin laborator və instrumental diaqnostikasına dair müasir yanaşmalar işıqlandırılmışdır. İltihab markerlərinin, HLA-B27 təyininin, oynaqların və entezislərin ultrasəs müayinəsinin, eləcə də aksial zədələnmələrin erkən aşkarlanması üçün ən informativ üsul hesab olunan maqnit-rezonans tomoqrafiyanın (MRT) rolu göstərilmişdir. Diferensial diaqnostikanın əsas prinsipləri və müasir medikamentoz müalicə yanaşmaları təqdim edilmişdir. Oynaq sindromunun vaxtında aşkar edilməsi və qastroenteroloq ilə revmatoloqun sıx multidissiplinar əməkdaşlığı oynaq strukturlarının zədələnməsinin qarşısının alınmasında, davamlı remissiyanın əldə edilməsində və İBX-li xəstələrin uzunmüddətli proqnozunun yaxşılaşdırılmasında həlledici əhəmiyyətə malikdir.
Açar sözlər: iltihabi bağırsaq xəstəlikləri, bağırsaqdankənar təzahürlər, oynaq sindromu, spondiloartrit, entezit, daktilit

---

ƏDƏBİYYAT

1. Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management // Gastroenter., 2021,161, 1118–1132. doi: 10.1053/j.gastro.2021.07. 042
2. Garber A, Regueiro M. Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis and Management // Curr Gastroenterol Rep., 2019; 21(7): 31. doi: 10.1007/s11894-019-0698-1
3. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis 2015; 21(8):1982–92. doi: 10.1097/MIB.0000000000000392
4. Roth N, Biedermann L, Fournier N, Vavriska SR, et al. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study // PLoS One. 2019; 14(1): e0210436. doi: 10.1371/journal.pone.0210436
5. Karmiris K, Avgerinos A, Tavernaraki A, Zeglinas Ch, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease // J Crohns Colitis., 2016; 10(4): 429–436. doi:10.1093/ecco-jcc/jjv232
6. Roberts H, Rai SN, Pan J, Rao JM, et al. Extraintestinal manifestations of inflammatory bowel disease and the influence of smoking // Digestion. 2014; 90(2): 122–29. doi:10.1159/000363228
7. Severs M, van Erp SJH, van der Valk ME, et al. Smoking is associated with extra-intestinal manifestations in inflammatory bowel disease // J Crohns Colitis., 2016; 10(4): 455–61. doi:10.1093/ecco-jcc/jjv238.11
8. Yang BR, Choi NK, Kim MS, Chun J, et al. Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients // PLoS One. 2018;13: e0200363. doi: 10.1371/journal.pone.0200363
9. Severs M, Spekhorst LM, Mangen MJ, Dijkstra J, et al. Sex-related differences in patients with inflammatory bowel disease: results of 2 prospective cohort studies // Inflamm Bowel Dis. 2018; 24:1298–1306. doi: 10.1093/ibd/izy004
10. Vavricka SR, Rogler G, Gantenbein C, Spoerri M, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort // Inflam. Bowel Dis. 2015 Aug;21(8):1794–1800. doi: 10.1097/MIB.0000000000000429
11. Harbord M, Annese V, Vavricka SR, Allez M, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease // J Crohns Colitis. 2016; 10(3):239-54. doi: 10.1093/ecco-jcc/jjv213
12. Gordon H, Burisch J, Ellul P, Karmiris K, et al. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease // J. Crohn’s Colitis, 2024 Jan 27;18(1):1-37. doi: 10.1093/ecco-jcc/jjad108
13. Faggiani I, Fanizza J, D'Amico F, Allocca M, et al. Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment // Biomedicines. 2024;12(8):1839. doi:10.3390/biomedicines12081839
14. Karreman MC, Luime JJ, Hazes JMW, Weel AEAM. The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis // J. Crohn’s Colitis 2017 May 1, 11(5), 631–642
15. Stolwijk C, Pierik M, Landewé R, Masclee A, et al. Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease // Can J Gastroenterol., 2013 Apr; 27(4):199-205. doi: 10.1155/2013/139702
16. Evans J, Sapsford M, McDonald S, Poole K, et al. Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: a systematic literature review // Ther Adv Musculoskelet Dis., 2021 Mar 11;13:1759720X21996973. doi: 10.1177/1759720X21996973
17. Felice C, Pugliese D, Papparella LG, Pizzolante F, et al. Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases // Expert Rev. Clin. Immunol., 2018, 14(9), 751–759. doi: 10.1080/1744666X.2018.1513329
18. Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease // World J Gastroen., 2009;15(20):2449–55. doi: 10.3748/wjg.15.2449
19. Sadygova G.G. Extraintestinal manifestations of inflammatory bowel diseases: arthropathy and arthritis // Ross gastroenterol gepatol. Koloproktol., 2016; 26(6):101-5. doi: 10.22416/1382-4376-2016-6-101-105
20. Malik TF, Aurelio DM. Extraintestinal Manifestations of Inflammatory Bowel Disease. [Updated 2023 Mar 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available: https://www.ncbi.nlm.nih. gov/books/ NBK 568797
21. Di Cola I, Vallocchia L, Cipriani P, Ruscitti P. Joint Manifestations in Inflammatory Bowel Diseases, "Red Flags" for the Early Recognition and Management of Related Arthropathies: A Narrative Review // J Clin Med., 2025 Feb 26;14(5):1558. doi: 10.3390/jcm14051558
22. Varkas G, Ribbens C, Louis E, Van den Bosch F, et al. Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies // Alimet Pharm. Ther. 2019; 50(11–12): 1204–13. doi:10.1111/ apt.1551
23. Ureyen S, Karacaer C, Toka B, Erturk Z, et al Similar subclinical enthesitis in celiac and IBD by ultrasound suggests a gut enthesis axis independent of spondyloarthropathy spectrum // Rheum. (Oxford). 2018 Aug 1;57(8):1417-1422. doi:10.1093/rheumatology/key102
24. Rovisco J, Duarte C, Batticcioto A, Sarzi-Puttini P, et al Hidden musculoskeletal involvement in IBD: a multicenter ultrasound study // BMC Musculoskeletal Disorders, 2016; 17:84. doi: 10.1186/s12891-016-0932-z
25. Akrapovic OI, Vukovic J, Radic M, Sundov Z. Enthesitis in IBD Patients // J Clin Med. 2024 Aug 3;13(15):4540. doi: 10.3390/jcm13154540
26. Sheth T, Pitchumoni CS, Das KM. Musculoskeletal manifestations in inflammatory bowel disease: A revisit in search of immunopathophysiological mechanisms // J. Clin. Gastr. 2014; 48:308–317. doi: 10.1097/MCG.0000000000 000067
27. Peluso R, Costa L, Caso F, Del Puente A, et al. Dactylitis in enteropathic spondyloarthritis // Clin. Exp. Rheumatol., 2016; 34(5):842–847
28. Horton DB, Sherry DD, Baldassano RN, Weiss P.F. Enthesitis is an extraintestinal manifestation of pediatric inflammatory bowel disease // Ann Paediatr Rheumatol., 2012; 1(4): doi:10.5455/apr.102920121510
29. Dougados M, Serrand C, Alonso S, Berenbaum F, et al. Ten-year clinical outcome of recent-onset axial spondyloarthritis: Results from the DESIR inception Cohort // Jt. Bone Spine. 2024; 91:105678. doi: 10.1016/j.jbspin.2023.105678
30. Felice C, Leccese P, Scudeller L, Lubrano E, et al. Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis // Clin. Exp. Immunol. 2019; 196:123–138. doi: 10.1111/cei.13246
31. Maaser C, Sturm A, Vavricka SR, Kucharzik T, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications // Journal of Crohn's and Colitis, 2019 Febr; Vol. 13, Issue 2, p. 144–164. doi:10.1093/ecco-jcc/jjy113
32. Bossuyt X. Serologic markers in inflammatory bowel disease // Clin Chem. 2006 Feb;52(2):171-81. doi: 10.1373/clinchem.2005.058560
33. De Vlam K, Mielants H, Cuvelier C, De Keyser F, et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: Prevalence and HLA association // J. Rheumatol. 2000;27(12):2860–2865
34. Becciolini A, Di Donato E, Lucchini G, Santilli D, et al. Imaging in the Assessment of Musculoskeletal Manifestations Associated with Inflammatory Bowel Disease // Gastroenterology Insights. 2021; 12(1):100-110. doi:10.3390/gastroent12010010
35. Guglielmi G, Scalzo G, Cascavilla A, Carotti M, et al. Imaging of the sacroiliac joint involvement in seronegative spondylarthropathies // Clin. Rheumatol., 2009; 28:1007–1019. doi: 10.1007/s10067-009-1192-1
36. Burge AJ, Nwawka OK, Berkowitz JL, Potter HG. Imaging of Inflammatory Arthritis in Adults: Status and Perspectives on the Use of Radiographs, Ultrasound and MRI // Rheum. Dis. Clin. N. Am. 2016, 42 (4), 561–585. doi: 10.1016/j.rdc.2016.07.001
37. Jones A, Bray TJP, Mandl P, Hall-Craggs MA, et al. Performance of magnetic resonance imaging in the diagnosis of axial spondyloarthritis: A systematic literature review // Rheumatology. 2019; 58:1955–1965. doi: 10.1093/rheumatology/kez172
38. Sudoł-Szopińska I, Jurik A, Eshed I, Lennart J, et al. Recommendations of the ESSR Arthritis Subcommittee for the Use of Magnetic Resonance Imaging in Musculoskeletal Rheumatic Diseases // Semin. Muscul. Radiol. 2015, 19(4), 396–411. doi: 10.1055/s-0035-1564696
39. Voulgari PV. Rheumatological manifestations in inflammatory bowel disease // Ann Gastroenterol., 2011;24(3):173-180. PMID: 24713717
40. Webers C, Ortolan A, Sepriano A, Falzon L, et al. Efficacy and safety of biological DMARDs: A systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis // Ann. Rheum. Dis., 2023; 82(1), 130–141. doi: 10.1136/ard-2022-223298
41. Iriarte A, Zaera C, Bachiller-Corral J, López-Sanromán A. Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy // Gastroenterol. Hepatol. 2017, 40(2), 117–121. doi: 10.1016/j.gastrohep.2016.01.011
42. Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, et al. Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study // Ann. Rheum. Dis. 2021, 80(8), 1004–1013. doi: 10.1136/annrheumdis-2020-219601
43. van der Heijde D, Baraliakos X, Sieper J, Deodhar A, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: A double-blind, randomised, placebo-controlled phase 3 trial // Ann. Rheum. Dis., 2022, 81(11), 1515–1523. doi: 10.1136/ard-2022-222608
44. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis // N. Engl. J. Med., 2022; 386 (4), p. 316-326. doi: 10.1056/NEJMoa2109927
45. Macaluso F.S, Fries W, Viola A, Costantino G, et al. Effectiveness of Ustekinumab on Crohn’s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) // Expert Opin. Biol. Ther., 2020, 20 (11), 1381–1384. doi: 10.1080/14712598.2020.1830057